BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25905981)

  • 1. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee SD; Kim SH; Kim SK; Kim YK; Park SJ
    Transplantation; 2015 Oct; 99(10):2142-9. PubMed ID: 25905981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
    Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
    Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation.
    Hsu CC; Chen CL; Wang CC; Lin CC; Yong CC; Wang SH; Liu YW; Lin TL; Lee WF; Lin YH; Chan YC; Wu YJ; Eng HL; Cheng YF
    Transplantation; 2016 Sep; 100(9):1925-32. PubMed ID: 27306534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
    Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
    World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of [
    Ye YF; Wang W; Wang T; Yu J; Geng L; Yu SF; Yan S; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):257-263. PubMed ID: 28603093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
    Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
    J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Utility of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Detecting Hepatocellular Carcinoma in Patients Before Liver Transplantation.
    Alotaibi F; Kabbani M; Abaalkhail F; Chorley A; Elbeshbeshy H; Al-Hamoudi W; Alabbad S; Boehnert MU; Alsofayan M; Al-Kattan W; Ahmed B; Broering D; Al Sebayel M; Elsiesy H
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):37-41. PubMed ID: 28260429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
    Asman Y; Evenson AR; Even-Sapir E; Shibolet O
    Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
    Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.
    Kim YI; Paeng JC; Cheon GJ; Suh KS; Lee DS; Chung JK; Kang KW
    J Nucl Med; 2016 Jul; 57(7):1045-51. PubMed ID: 26985057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma.
    Yokoi H; Isaji S; Yamagiwa K; Tabata M; Nemoto A; Sakurai H; Usui M; Uemoto S
    J Hepatobiliary Pancreat Surg; 2006; 13(2):123-30. PubMed ID: 16547673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.